Forrest JK, Ramlawi B, Deeb GM, et al. - Researchers undertook this single-arm prospective study (Low Risk Bicuspid Study) to assess the procedural safety, efficacy, as well as 30-day results of transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis at low surgical risk. A total of 150 low-risk patients with bicuspid aortic valve stenosis received TAVR employing a self-expanding valve and a standardized sizing strategy. At 30 days, the estimated incidence of all-cause death or disabling stroke was 1.3%. Device success rate was estimated to be 95.3%. The mean (SD) AV gradient was found to be 7.6 (3.7) mm Hg and effective orifice area was 2.3 (0.7) cm² at 30 days. Overall, favorable 30-day results were provided by TAVR in low–surgical risk patients with bicuspid aortic valve stenosis. TAVR conferred low rates of death and stroke and high device success rate in these patients.